Association of Uremic Solutes With Cardiovascular Death in Diabetic Kidney Disease.
暂无分享,去创建一个
R. Vasan | P. Kimmel | T. Hostetter | H. Feldman | M. Shlipak | M. Sarnak | R. Katz | M. Cushman | J. Ix | E. Rhee | H. Brunengraber | J. Schelling | O. Gutiérrez | Jesse C. Seegmiller | Sarah J. Schrauben | H. Sapa
[1] N. Powe,et al. New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race. , 2021, The New England journal of medicine.
[2] S. Waikar,et al. Urinary Biomarkers and Kidney Outcomes: Impact of Indexing Versus Adjusting for Urinary Creatinine , 2021, Kidney medicine.
[3] B. Urquhart,et al. Uremic Toxins in the Progression of Chronic Kidney Disease and Cardiovascular Disease: Mechanisms and Therapeutic Targets , 2021, Toxins.
[4] R. Gansevoort,et al. Use of the Urine-to-Plasma Urea Ratio to Predict ADPKD Progression. , 2021, Clinical journal of the American Society of Nephrology : CJASN.
[5] M. Krempf,et al. Elevation of Trimethylamine-N-Oxide in Chronic Kidney Disease: Contribution of Decreased Glomerular Filtration Rate , 2019, Toxins.
[6] J. Rodriguez-Perez,et al. Asymmetric (ADMA) and Symmetric (SDMA) Dimethylarginines in Chronic Kidney Disease: A Clinical Approach , 2019, International journal of molecular sciences.
[7] Angela M. Malek,et al. The association of age at menopause and all-cause and cause-specific mortality by race, postmenopausal hormone use, and smoking status , 2019, Preventive medicine reports.
[8] T. Meyer,et al. Uremic Toxin Clearance and Cardiovascular Toxicities , 2018, Toxins.
[9] D. Fliser,et al. Symmetric dimethylarginine (SDMA) outperforms asymmetric dimethylarginine (ADMA) and other methylarginines as predictor of renal and cardiovascular outcome in non-dialysis chronic kidney disease , 2018, Clinical Research in Cardiology.
[10] K. Maeda,et al. Involvement of Organic Cation Transporters in the Kinetics of Trimethylamine N-oxide. , 2017, Journal of pharmaceutical sciences.
[11] W. Lieb,et al. Asymmetric and symmetric dimethylarginine as risk markers for total mortality and cardiovascular outcomes: A systematic review and meta-analysis of prospective studies. , 2017, Atherosclerosis.
[12] H. Parving,et al. Symmetric and asymmetric dimethylarginine as risk markers of cardiovascular disease, all-cause mortality and deterioration in kidney function in persons with type 2 diabetes and microalbuminuria , 2017, Cardiovascular Diabetology.
[13] Wei Wu,et al. Key Role for the Organic Anion Transporters, OAT1 and OAT3, in the in vivo Handling of Uremic Toxins and Solutes , 2017, Scientific Reports.
[14] W. Lieb,et al. Asymmetric and Symmetric Dimethylarginine as Risk Markers for Total Mortality and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Prospective Studies , 2016, PloS one.
[15] Lena Osterhagen,et al. Multiple Imputation For Nonresponse In Surveys , 2016 .
[16] J. Spertus,et al. Serum Trimethylamine-N-Oxide is Elevated in CKD and Correlates with Coronary Atherosclerosis Burden. , 2016, Journal of the American Society of Nephrology : JASN.
[17] T. Meyer,et al. Mechanism of Prominent Trimethylamine Oxide (TMAO) Accumulation in Hemodialysis Patients , 2015, PloS one.
[18] K. Aasarød,et al. Arginine, dimethylated arginine and homoarginine in relation to cardiovascular risk in patients with moderate chronic kidney disease. , 2015, Clinical biochemistry.
[19] S. Hazen,et al. Gut Microbiota-Dependent Trimethylamine N-Oxide (TMAO) Pathway Contributes to Both Development of Renal Insufficiency and Mortality Risk in Chronic Kidney Disease , 2015, Circulation research.
[20] U. Patel,et al. Cardiovascular complications of diabetic kidney disease. , 2014, Advances in chronic kidney disease.
[21] D. Fliser,et al. Dimethylarginines ADMA and SDMA: the real water-soluble small toxins? , 2014, Seminars in nephrology.
[22] H. Völzke,et al. Incidence of All-Cause and Cardiovascular Mortality Predicted by Symmetric Dimethylarginine in the Population-Based Study of Health in Pomerania , 2013, PloS one.
[23] A. Khera,et al. Symmetrical Dimethylarginine Predicts Mortality in the General Population: Observations From the Dallas Heart Study , 2013, Arteriosclerosis, thrombosis, and vascular biology.
[24] Kamyar Kalantar-Zadeh,et al. Cardiovascular Burden Associated with Uremic Toxins in Patients with Chronic Kidney Disease , 2013, American Journal of Nephrology.
[25] S. Hazen,et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. , 2013, The New England journal of medicine.
[26] A. Akhmedov,et al. Abnormal high-density lipoprotein induces endothelial dysfunction via activation of Toll-like receptor-2. , 2013, Immunity.
[27] Katrin Uhlig,et al. Risk Prediction Models for Patients With Chronic Kidney Disease , 2013, Annals of Internal Medicine.
[28] F. Bushman,et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis , 2013, Nature Medicine.
[29] Harold I Feldman,et al. Plasma metabolomic profiles in different stages of CKD. , 2013, Clinical journal of the American Society of Nephrology : CJASN.
[30] John A. Cornell,et al. Statistical Methods (7th ed.) , 2012 .
[31] Brian J. Bennett,et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease , 2011, Nature.
[32] R. Gerszten,et al. Metabolite profiling identifies markers of uremia. , 2010, Journal of the American Society of Nephrology : JASN.
[33] G. Beck,et al. Asymmetric dimethylarginine and mortality in stages 3 to 4 chronic kidney disease. , 2009, Clinical journal of the American Society of Nephrology : CJASN.
[34] C. Schmid,et al. A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.
[35] E. Benjamin,et al. Plasma Asymmetric Dimethylarginine and Incidence of Cardiovascular Disease and Death in the Community , 2009, Circulation.
[36] H. Mischak,et al. Review on uraemic solutes II--variability in reported concentrations: causes and consequences. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[37] J. Griffith,et al. The Framingham predictive instrument in chronic kidney disease. , 2007, Journal of the American College of Cardiology.
[38] R. Milne,et al. Accumulation of trimethylamine and trimethylamine-N-oxide in end-stage renal disease patients undergoing haemodialysis. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[39] G. Breithardt,et al. Symmetrical dimethylarginine: a new combined parameter for renal function and extent of coronary artery disease. , 2006, Journal of the American Society of Nephrology : JASN.
[40] G. Wolf,et al. Asymmetrical (ADMA) and symmetrical dimethylarginine (SDMA) as potential risk factors for cardiovascular and renal outcome in chronic kidney disease – possible candidates for paradoxical epidemiology? , 2006, Amino Acids.
[41] C. Moy,et al. The Reasons for Geographic and Racial Differences in Stroke Study: Objectives and Design , 2005, Neuroepidemiology.
[42] F. Kronenberg,et al. Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. , 2005, Journal of the American Society of Nephrology : JASN.
[43] Charles E McCulloch,et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. , 2004, The New England journal of medicine.
[44] P. Royston. Multiple Imputation of Missing Values , 2004 .
[45] Deeb N Salem,et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. , 2004, Journal of the American Society of Nephrology : JASN.
[46] H. Prins,et al. Handling of asymmetrical dimethylarginine and symmetrical dimethylarginine by the rat kidney under basal conditions and during endotoxaemia. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[47] F. Schweitzer,et al. Serum concentrations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine in patients with chronic kidney diseases. , 2003, Clinica chimica acta; international journal of clinical chemistry.
[48] D. Levy,et al. Prediction of coronary heart disease using risk factor categories. , 1998, Circulation.
[49] R. Anderson,et al. Urinary diagnostic indices in acute renal failure: a prospective study. , 1978, Annals of internal medicine.
[50] Joshua Lederberg,et al. Children's Hospital of Philadelphia. , 1975, The Australasian nurses journal.
[51] E. N. Allott,et al. UREMIA , 1963 .